Zultan3 ml

Zultan ophthalmic solution is FDA-approved for the following indication:

• Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Zultan is typically used as a first-line topical agent, either alone or, when IOP control is insufficient, as part of combination therapy with other IOP-lowering eye drops (e.g., beta-blockers, carbonic anhydrase inhibitors, or alpha-agonists) under a physician's guidance. There are no well-established guideline-supported uses beyond glaucoma/ocular hypertension, and no commonly recognized off-label indications for Zultan.

Each mL of Latanoprostene Bunod ophthalmic solution contains:

• Latanoprostene Bunod 0.024% (0.24 mg/mL)

Inactive ingredients typically include benzalkonium chloride (as a preservative), boric acid, mannitol, polyoxyl 40 stearate, edetate disodium, water for injection, and sodium hydroxide/hydrochloric acid for pH adjustment.

Zultan is a once-daily ophthalmic (eye) prostaglandin analog formulated as a 0.024% sterile solution for topical use in the eye. It is a dual-acting molecule: after instillation it is metabolized into latanoprost acid (a prostaglandin F2-alpha analog) and butanediol mononitrate, which releases nitric oxide (NO). This combination lowers intraocular pressure through two complementary outflow pathways, distinguishing Zultan from single-mechanism prostaglandin analogs.

Latanoprostene Bunod is a nitric oxide-donating prostaglandin F2-alpha analog. Following topical ocular administration, Latanoprostene Bunod is hydrolyzed by esterases in the eye into two active moieties:

• Latanoprost acid, which lowers intraocular pressure primarily by increasing aqueous humor outflow through the uveoscleral (unconventional) pathway.
• Butanediol mononitrate, which is further metabolized to release nitric oxide (NO), thought to relax the trabecular meshwork and Schlemm's canal, increasing outflow through the trabecular meshwork (conventional) pathway.

By acting on both outflow pathways, Latanoprostene Bunod produces a greater or more consistent reduction in intraocular pressure than agents that act on a single pathway alone. Onset of IOP-lowering effect begins within a few hours, with peak effect around 12 hours after dosing; systemic absorption is minimal after ocular instillation.

Zultan is for topical ophthalmic use only (into the eye), not for oral, injectable, or any other route of use.

• Wash hands before use.
• Tilt the head back, gently pull down the lower eyelid to form a pocket, and instill one drop into the affected eye(s).
• Avoid letting the dropper tip touch the eye, eyelid, or any other surface to prevent contamination.
• If using other topical ophthalmic medications, space administration at least 5 minutes apart.
• Contact lenses should be removed before instillation (the solution contains benzalkonium chloride, which may be absorbed by soft contact lenses) and may be reinserted 15 minutes after administration.

Zultan is applied topically to the eye and has minimal systemic absorption, so clinically significant systemic drug interactions are not well established.

• Other topical prostaglandin analogs: concurrent use with other prostaglandin-class eye drops is not recommended, as it does not provide additional IOP-lowering benefit and may increase local side effects.
• Other topical ophthalmic medications: if more than one topical ophthalmic drug is being used, doses should be administered at least 5 minutes apart to prevent one medication from washing out the other.

Inform the prescribing physician of all other eye drops or medications in use before starting Zultan.

The most common side effect of Zultan is:

• Conjunctival hyperemia (eye redness) — the most frequently reported adverse reaction.

Other reported side effects include:

• Eye irritation, eye pain, or a stinging/burning sensation on instillation
• Instillation-site pain
• Blurred vision
• Increased growth, thickness, pigmentation, or number of eyelashes
• Foreign body sensation in the eye
• Dry eye and eye pruritus (itching)

Less common but clinically important effects include gradual, permanent increase in brown iris pigmentation and macular edema (see Precautions and Warnings for details). Patients should report persistent, severe, or worsening eye symptoms to their physician.

Pregnancy: There are no adequate and well-controlled studies of Zultan in pregnant women. Zultan should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus. Use only if clearly needed and under the direct advice of a physician.

Lactation: It is not known whether Zultan or its metabolites are excreted in human breast milk. Caution should be exercised when Zultan is administered to a breastfeeding woman, and a physician should be consulted before use during breastfeeding.

The following precautions apply to the use of Zultan:

• Pigmentation changes: Zultan may cause a gradual change in eye color by increasing the amount of brown pigment in the iris. This change may be permanent and is more noticeable in patients with mixed-color irises (e.g., blue-brown, gray-brown, yellow-brown, or green-brown). Periorbital and eyelid skin pigmentation changes have also been reported and may be reversible.
• Eyelash changes: gradual increase in eyelash length, thickness, and pigmentation may occur.
• Macular edema: has been reported during treatment; caution is advised in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or those with other known risk factors for macular edema.
• Intraocular inflammation: Zultan should be used with caution in patients with active intraocular inflammation (iritis/uveitis), as inflammation may be exacerbated.
• Bacterial keratitis: has been associated with contamination of multidose ophthalmic solution containers; avoid touching the dropper tip to any surface.
• Contact lenses: should be removed before instillation and may be reinserted 15 minutes later.

Zultan is not an antibiotic and has no role in treating eye infections.

Ocular overdose of Zultan may cause increased local irritation, conjunctival hyperemia, or excessive watering of the eye. If oral ingestion of the product occurs, or if excessive amounts are instilled, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt unsupervised home treatment for suspected overdose or ingestion.

Pediatric use: Safety and efficacy of Zultan have not been established in pediatric patients below 18 years of age.

Geriatric use: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients; no dose adjustment is required based on age alone.

Renal/hepatic impairment: No specific dose adjustment has been established or is expected to be necessary, given minimal systemic absorption after topical ocular administration.

Pregnancy and lactation: See Pregnancy and Lactation section above.

Zultan is generally used for chronic, long-term daily management of open-angle glaucoma or ocular hypertension, as these are typically lifelong conditions requiring ongoing IOP control. Duration of treatment should be determined by the treating ophthalmologist based on regular monitoring of intraocular pressure, optic nerve status, and visual field, and treatment should not be stopped or altered without medical advice.

Latanoprostene Bunod works by lowering intraocular pressure through two complementary mechanisms:

• Its metabolite latanoprost acid increases aqueous humor outflow via the uveoscleral pathway.
• Its metabolite butanediol mononitrate releases nitric oxide, which is believed to relax the trabecular meshwork and Schlemm's canal, increasing outflow via the trabecular meshwork pathway.

This dual-pathway action distinguishes Latanoprostene Bunod from prostaglandin analogs that act on the uveoscleral pathway alone.